argenx SE (ARGNF)
OTCMKTS
· Delayed Price · Currency is USD
697.42
+72.12 (11.53%)
At close: Jan 29, 2025
argenx SE Employees
argenx SE had 1,599 employees as of December 31, 2024. The number of employees increased by 451 or 39.29% compared to the previous year.
Employees
1,599
Change (1Y)
451
Growth (1Y)
39.29%
Revenue / Employee
$1,406,007
Profits / Employee
$520,976
Market Cap
35.64B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 2,931 |
Elite Pharmaceuticals | 64 |
Glass House Brands | 413 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
Silence Therapeutics | 116 |
American Oncology Network | 1,525 |
argenx SE News
- 5 days ago - Looking Into argenx's Recent Short Interest - Benzinga
- 7 days ago - Argenx: The Magic May Be Already Priced In - Seeking Alpha
- 11 days ago - P/E Ratio Insights for argenx - Benzinga
- 24 days ago - argenx SE (ARGX) Announces Promising Data for VYVGART at AAN Annual Meeting - GuruFocus
- 24 days ago - argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting - GlobeNewsWire
- 4 weeks ago - argenx targets 12,000 CIDP patients with VYVGART expansion in 2025 - Seeking Alpha
- 4 weeks ago - argenx SE (ARGX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent - Seeking Alpha